These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25079599)

  • 1. A comparison of multidrug-resistant tuberculosis treatment commencement times in MDRTBPlus line probe assay and Xpert® MTB/RIF-based algorithms in a routine operational setting in Cape Town.
    Naidoo P; du Toit E; Dunbar R; Lombard C; Caldwell J; Detjen A; Squire SB; Enarson DA; Beyers N
    PLoS One; 2014; 9(7):e103328. PubMed ID: 25079599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Has universal screening with Xpert® MTB/RIF increased the proportion of multidrug-resistant tuberculosis cases diagnosed in a routine operational setting?
    Naidoo P; Dunbar R; Caldwell J; Lombard C; Beyers N
    PLoS One; 2017; 12(2):e0172143. PubMed ID: 28199375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Tuberculosis Diagnostic Yield in Smear/Culture and Xpert® MTB/RIF-Based Algorithms Using a Non-Randomised Stepped-Wedge Design.
    Naidoo P; Dunbar R; Lombard C; du Toit E; Caldwell J; Detjen A; Squire SB; Enarson DA; Beyers N
    PLoS One; 2016; 11(3):e0150487. PubMed ID: 26930400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests.
    Naidoo P; van Niekerk M; du Toit E; Beyers N; Leon N
    BMC Health Serv Res; 2015 Oct; 15():488. PubMed ID: 26511931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementation and Operational Research: Clinical Impact of the Xpert MTB/RIF Assay in Patients With Multidrug-Resistant Tuberculosis.
    Padayatchi N; Naidu N; Yende-Zuma N; OʼDonnell MR; Naidoo K; Augustine S; Zumla A; Loveday M
    J Acquir Immune Defic Syndr; 2016 Sep; 73(1):e1-7. PubMed ID: 27509173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing laboratory costs of smear/culture and Xpert
    Naidoo P; Dunbar R; du Toit E; van Niekerk M; Squire SB; Beyers N; Madan J
    Int J Tuberc Lung Dis; 2016 Oct; 20(10):1377-1385. PubMed ID: 27725051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing multidrug-resistant tuberculosis patient costs under molecular diagnostic algorithms in South Africa.
    du Toit E; Squire SB; Dunbar R; Machekano R; Madan J; Beyers N; Naidoo P
    Int J Tuberc Lung Dis; 2015 Aug; 19(8):960-8. PubMed ID: 26162363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the Xpert MTB/RIF Assay in Multidrug-Resistant Tuberculosis.
    Tabriz NS; Skak K; Kassayeva LT; Omarkulov BK; Grigolashvili MA
    Microb Drug Resist; 2020 Aug; 26(8):997-1004. PubMed ID: 32181685
    [No Abstract]   [Full Text] [Related]  

  • 11. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
    Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
    PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic accuracy and turnaround time of the Xpert MTB/RIF assay in routine clinical practice.
    Kwak N; Choi SM; Lee J; Park YS; Lee CH; Lee SM; Yoo CG; Kim YW; Han SK; Yim JJ
    PLoS One; 2013; 8(10):e77456. PubMed ID: 24204834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Xpert MTB/RIF on the treatment of multi-drug-resistant or rifampicin-resistant tuberculosis screened out from re-treatment pulmonary tuberculosis patients, a prospective cohort study.
    Wang P; Gu J; Yang J; Yang C; Wu X; Yu F; Fan L
    Ann Palliat Med; 2020 Mar; 9(2):239-246. PubMed ID: 32233619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF-resistant and RIF-susceptible TB patients in Vladimir TB dispensary, Russia.
    Ershova JV; Volchenkov GV; Somova TR; Kuznetsova TA; Kaunetis NV; Kaminski D; Demikhova OV; Chernousova LN; Vasilyeva IA; Kerr EM; Cegielski JP; Kurbatova EV
    BMC Infect Dis; 2020 Jul; 20(1):543. PubMed ID: 32711457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.
    Scott LE; McCarthy K; Gous N; Nduna M; Van Rie A; Sanne I; Venter WF; Duse A; Stevens W
    PLoS Med; 2011 Jul; 8(7):e1001061. PubMed ID: 21814495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
    Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
    PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.
    Steingart KR; Schiller I; Horne DJ; Pai M; Boehme CC; Dendukuri N
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009593. PubMed ID: 24448973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving rifampicin-resistant tuberculosis diagnosis using Xpert
    Dunbar R; Naidoo P; Beyers N; Langley I
    Int J Tuberc Lung Dis; 2018 Aug; 22(8):890-898. PubMed ID: 29991398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xpert®MTB/RIF for the Diagnosis of Tuberculosis in a Remote Arctic Setting: Impact on Cost and Time to Treatment Initiation.
    Oxlade O; Sugarman J; Alvarez GG; Pai M; Schwartzman K
    PLoS One; 2016; 11(3):e0150119. PubMed ID: 26990299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifampicin resistance mutations in the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF in Kampala, Uganda: a retrospective study.
    Mboowa G; Namaganda C; Ssengooba W
    BMC Infect Dis; 2014 Sep; 14():481. PubMed ID: 25190040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.